9
15. 9. 2022.
The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A
Key Points • Rondaptivon pegol is a first-in-class prohemostatic molecule that prolongs the half-life of both endogenous FVIII and substituted FVIII.• Rondaptivon pegol could be used to enable once-weekly substitution therapy in severe hemophilia A or as prophylaxis in nonsevere hemophilia A.